HK1175471A1 - 非核苷類逆轉錄酶抑制劑 - Google Patents

非核苷類逆轉錄酶抑制劑

Info

Publication number
HK1175471A1
HK1175471A1 HK13102950.9A HK13102950A HK1175471A1 HK 1175471 A1 HK1175471 A1 HK 1175471A1 HK 13102950 A HK13102950 A HK 13102950A HK 1175471 A1 HK1175471 A1 HK 1175471A1
Authority
HK
Hong Kong
Prior art keywords
reverse transcriptase
transcriptase inhibitors
nucleoside reverse
nucleoside
inhibitors
Prior art date
Application number
HK13102950.9A
Other languages
English (en)
Inventor
Jason Burch
Bernard Cote
Natalie Nguyen
Chun Sing Li
Miguel St-Onge
Danny Gauvreau
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1175471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of HK1175471A1 publication Critical patent/HK1175471A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
HK13102950.9A 2010-03-30 2013-03-09 非核苷類逆轉錄酶抑制劑 HK1175471A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US32157310P 2010-04-07 2010-04-07
PCT/CA2011/000320 WO2011120133A1 (en) 2010-03-30 2011-03-28 Non-nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
HK1175471A1 true HK1175471A1 (zh) 2013-07-05

Family

ID=44710363

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13102950.9A HK1175471A1 (zh) 2010-03-30 2013-03-09 非核苷類逆轉錄酶抑制劑
HK15109888.9A HK1209121A1 (zh) 2010-03-30 2015-10-09 包含非核苷逆轉錄酶抑制劑的藥物組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15109888.9A HK1209121A1 (zh) 2010-03-30 2015-10-09 包含非核苷逆轉錄酶抑制劑的藥物組合物

Country Status (44)

Country Link
US (2) US8486975B2 (zh)
EP (2) EP2552902B1 (zh)
JP (2) JP5281718B2 (zh)
KR (1) KR101421861B1 (zh)
CN (1) CN102971308B (zh)
AR (1) AR080859A1 (zh)
AU (1) AU2011235568B2 (zh)
BR (1) BR112012024691B1 (zh)
CA (1) CA2794377C (zh)
CL (1) CL2012002744A1 (zh)
CO (1) CO6630126A2 (zh)
CR (1) CR20120503A (zh)
CY (3) CY1118774T1 (zh)
DK (2) DK2924034T3 (zh)
DO (1) DOP2012000256A (zh)
EA (1) EA024804B1 (zh)
EC (1) ECSP12012201A (zh)
ES (2) ES2536295T3 (zh)
FI (1) FIC20190021I1 (zh)
GE (1) GEP20156368B (zh)
HK (2) HK1175471A1 (zh)
HN (1) HN2012002039A (zh)
HR (2) HRP20150427T1 (zh)
HU (4) HUE025336T2 (zh)
IL (2) IL222030A (zh)
LT (3) LT2924034T (zh)
LU (2) LUC00114I2 (zh)
MA (1) MA34170B1 (zh)
ME (2) ME02181B (zh)
MX (1) MX2012011379A (zh)
MY (1) MY163979A (zh)
NI (1) NI201200146A (zh)
NL (1) NL300980I2 (zh)
NO (2) NO2019018I1 (zh)
NZ (1) NZ602670A (zh)
PE (1) PE20130158A1 (zh)
PL (2) PL2924034T3 (zh)
PT (2) PT2552902E (zh)
RS (2) RS54017B1 (zh)
SG (1) SG184347A1 (zh)
SI (2) SI2552902T1 (zh)
TN (1) TN2012000455A1 (zh)
TW (1) TWI458719B (zh)
WO (1) WO2011120133A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2552902B1 (en) * 2010-03-30 2015-03-11 Merck Canada Inc. Non-nucleoside reverse transcriptase inhibitors
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
US9150539B2 (en) 2012-09-26 2015-10-06 Merck Sharp & Dohme Corp. Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
WO2014089140A1 (en) 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
BR112016011605A8 (pt) * 2013-11-22 2023-04-25 Merck Sharp & Dohme Composição de um inibidor de transcriptase reversa não nucleosídeo
US9598397B2 (en) 2013-12-04 2017-03-21 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
ES2828951T3 (es) 2014-04-01 2021-05-28 Merck Sharp & Dohme Profármacos de inhibidores de la transcriptasa inversa del VIH
HRP20211687T1 (hr) 2015-12-02 2022-03-04 Merck Sharp & Dohme Corp. Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
CN110769856A (zh) 2017-04-18 2020-02-07 希普拉有限公司 用于治疗逆转录病毒感染的组合疗法
US20210213041A1 (en) 2018-02-06 2021-07-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
US12005072B2 (en) 2018-07-17 2024-06-11 Merck Sharp & Dohme Llc HIV drug combination for increasing barrier against resistance
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
CA2563180C (en) 2004-04-23 2013-08-06 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US20090264425A1 (en) 2004-12-22 2009-10-22 Pfizer Limited Chemical compounds
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
AU2006303367A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
JP5539216B2 (ja) 2007-11-20 2014-07-02 メルク・シャープ・アンド・ドーム・コーポレーション 非ヌクレオシド系逆転写酵素阻害剤
EP2552902B1 (en) * 2010-03-30 2015-03-11 Merck Canada Inc. Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
LUC00114I2 (zh) 2020-07-10
HUS1900021I1 (hu) 2019-05-28
RS55505B1 (sr) 2017-05-31
NO2019018I1 (no) 2019-04-24
TWI458719B (zh) 2014-11-01
CN102971308B (zh) 2015-02-04
AU2011235568A1 (en) 2012-11-01
EP2924034B1 (en) 2016-11-02
AR080859A1 (es) 2012-05-16
ME02570B (me) 2017-06-20
JP5886790B2 (ja) 2016-03-16
DOP2012000256A (es) 2012-12-15
JP2013510800A (ja) 2013-03-28
CA2794377A1 (en) 2011-10-06
EP2552902A4 (en) 2013-09-04
PE20130158A1 (es) 2013-02-28
CR20120503A (es) 2013-01-09
EP2924034A1 (en) 2015-09-30
WO2011120133A1 (en) 2011-10-06
ECSP12012201A (es) 2012-10-30
TN2012000455A1 (en) 2014-01-30
TW201139409A (en) 2011-11-16
MX2012011379A (es) 2012-11-30
SI2552902T1 (sl) 2015-10-30
CY2019025I1 (el) 2019-11-27
DK2924034T3 (en) 2017-02-06
HK1209121A1 (zh) 2016-03-24
PL2552902T3 (pl) 2015-10-30
KR20120128703A (ko) 2012-11-27
ES2609636T3 (es) 2017-04-21
NI201200146A (es) 2013-03-18
EA201290976A1 (ru) 2013-03-29
GEP20156368B (en) 2015-09-25
LUC00114I1 (zh) 2019-04-17
RS54017B1 (en) 2015-10-30
CL2012002744A1 (es) 2012-12-14
CY2019025I2 (el) 2019-11-27
MY163979A (en) 2017-11-15
IL233334A0 (en) 2014-09-01
US20110245296A1 (en) 2011-10-06
PT2924034T (pt) 2017-01-06
CY1118774T1 (el) 2017-07-12
LTPA2019506I1 (lt) 2019-04-25
NZ602670A (en) 2014-09-26
NO2019019I1 (no) 2019-04-24
ES2536295T3 (es) 2015-05-22
SG184347A1 (en) 2012-11-29
DK2552902T3 (en) 2015-06-15
CY2019026I2 (el) 2020-05-29
AU2011235568B2 (en) 2013-09-12
LTC2552902I2 (lt) 2019-12-10
PL2924034T3 (pl) 2017-07-31
LUC00113I9 (zh) 2024-06-07
NL300980I1 (nl) 2019-04-24
HUE031785T2 (en) 2017-08-28
LUC00113I2 (zh) 2024-05-22
CN102971308A (zh) 2013-03-13
BR112012024691B1 (pt) 2020-11-17
HRP20150427T1 (hr) 2015-07-03
FIC20190021I1 (fi) 2019-04-17
EA024804B1 (ru) 2016-10-31
KR101421861B1 (ko) 2014-07-22
NL300980I2 (nl) 2021-06-17
LTPA2019507I1 (lt) 2019-04-25
US20130296382A1 (en) 2013-11-07
CA2794377C (en) 2015-06-16
CO6630126A2 (es) 2013-03-01
SI2924034T1 (sl) 2017-05-31
ME02181B (me) 2015-10-20
HUS1900022I1 (hu) 2019-05-28
EP2552902B1 (en) 2015-03-11
HUE025336T2 (en) 2016-03-29
BR112012024691A2 (pt) 2019-07-02
LTC2924034I2 (lt) 2020-10-12
EP2552902A1 (en) 2013-02-06
CY2019026I1 (el) 2020-05-29
LT2924034T (lt) 2016-12-27
IL222030A (en) 2014-07-31
JP2013209405A (ja) 2013-10-10
US8486975B2 (en) 2013-07-16
MA34170B1 (fr) 2013-04-03
PT2552902E (pt) 2015-06-02
HRP20161680T1 (hr) 2017-01-27
JP5281718B2 (ja) 2013-09-04
IL233334A (en) 2015-09-24
HN2012002039A (es) 2015-08-24

Similar Documents

Publication Publication Date Title
HUS1900021I1 (hu) Nem nukleozid reverz transzkriptáz inhibitorok
EP2604688A4 (en) VARIANTE REVERSE TRANSKRIPTASE
HK1177205A1 (zh) 惡唑的激酶抑制劑
EP2622448A4 (en) EXPANSION OF A DESKTOP DISPLAY
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
EP2739221A4 (en) SURGICAL ANCHOR
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
HK1198827A1 (zh) 抑制劑及其用途
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
EP2217069A4 (en) INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE
IL205386A0 (en) Non - nucleoside reverse transcriptase inhibitors
GB201009731D0 (en) Kinase inhibitors
GB201016880D0 (en) Phosphodiesterase inhibitors
GB201002959D0 (en) Tissue expander
ZA201206456B (en) Uses of dgati inhibitors
PL2533962T3 (pl) Kołek rozporowy
EP2563127A4 (en) PROLYLCARBOXYPEPTIDASE INHIBITORS
GB201009853D0 (en) HSP90 inhibitors
IL200886A0 (en) Non-nucleoside reverse transcriptase inhibitors
IL202143A0 (en) Non-nucleoside reverse transcriptase inhibitors
TWM388314U (en) Expander
GB201018597D0 (en) Inhibitors
GB201120474D0 (en) Inhibitors
GB201006605D0 (en) Novel inhibitors